Aliases & Classifications for Mucositis

MalaCards integrated aliases for Mucositis:

Name: Mucositis 12 55 44 15
Inflammatory Disease of Mucous Membrane 73
Gastrointestinal Mucositis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0080178
MeSH 44 D052016

Summaries for Mucositis

Disease Ontology : 12 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary : Mucositis, also known as inflammatory disease of mucous membrane, is related to kaposi sarcoma and diphtheria, and has symptoms including signs and symptoms, digestive, oral manifestations and catarrh. An important gene associated with Mucositis is CSF2 (Colony Stimulating Factor 2), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Nystatin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lung, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 76 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Related Diseases for Mucositis

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 868)
# Related Disease Score Top Affiliating Genes
1 kaposi sarcoma 31.5 CSF2 MTOR VEGFA
2 diphtheria 29.9 CSF2 EGF IL2
3 gastric cancer 29.9 ABCB1 DPYD EGF FGF7 MTHFR TYMS
4 myeloma, multiple 29.7 ABCB1 CSF2 CSF3 IL2 VEGFA
5 stomatitis 29.7 CSF2 CSF3 DPYD FGF7 MTOR
6 acute leukemia 29.6 ABCB1 CSF3 MTHFR
7 osteonecrosis 29.6 ABCB1 MTHFR VEGFA
8 intestinal disease 29.5 IL2 TYMS VEGFA
9 acute lymphocytic leukemia 29.5 CSF2 CSF3 IL2 MTHFR TYMS
10 lymphoma, non-hodgkin, familial 29.4 ABCB1 CSF2 CSF3 IL2
11 leukemia, acute myeloid 29.2 ABCB1 CSF2 CSF3 IL2 MTOR
12 adamantinoma of long bones 29.2 ABCB1 CSF2 EGF VEGFA
13 renal cell carcinoma, nonpapillary 29.1 ABCB1 CSF2 IL2 MTOR VEGFA
14 gastrointestinal carcinoma 29.1 ABCB1 DPYD TYMS
15 cardia cancer 29.0 MTHFR TYMS XRCC1
16 autosomal dominant polycystic kidney disease 29.0 EGF MTOR VEGFA
17 malaria 28.9 CSF2 CSF3 IL2 TYMS VEGFA
18 colorectal cancer 28.6 ABCB1 DPYD EGF MTHFR MTOR TYMS
19 venous malformations, multiple cutaneous and mucosal 12.5
20 mucosal melanoma 12.5
21 multiple mucosal neuroma 12.2
22 multiple endocrine neoplasia, type iib 12.0
23 white sponge nevus 1 11.8
24 cicatricial pemphigoid 11.8
25 ocular cicatricial pemphigoid 11.7
26 gastritis 11.5
27 melanoma 11.4
28 mallory-weiss syndrome 11.3
29 squamous cell carcinoma, head and neck 11.3
30 lymphoma, mucosa-associated lymphoid type 11.3
31 schimmelpenning-feuerstein-mims syndrome 11.3
32 allergic rhinitis 11.2
33 gastritis, familial giant hypertrophic 11.2
34 oral candidiasis 11.2
35 severe cutaneous adverse reaction 11.2
36 eosinophilic gastroenteritis 11.2
37 esophageal varix 11.2
38 granular cell tumor 11.2
39 intestinal tuberculosis 11.1
40 cyclic neutropenia 11.1
41 hemophilia a 11.1
42 exstrophy of bladder 11.1
43 chronic mucocutaneous candidiasis 11.1
44 lassa fever 11.1
45 immunoglobulin a deficiency 1 11.1
46 telangiectasia, hereditary hemorrhagic, type 4 11.1
47 plasminogen deficiency, type i 11.0
48 factor x deficiency 11.0
49 bleeding disorder, platelet-type, 8 11.0
50 dyskeratosis congenita, autosomal dominant 2 11.0

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis

Symptoms & Phenotypes for Mucositis

UMLS symptoms related to Mucositis:


signs and symptoms, digestive, oral manifestations, catarrh

MGI Mouse Phenotypes related to Mucositis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 ABCB1 CSF2 EGF FGF7 HTR3A IL2
2 behavior/neurological MP:0005386 10.18 ABCB1 CSF2 FGF7 HTR3A IL2 MTOR
3 homeostasis/metabolism MP:0005376 10.14 ABCB1 CSF2 FGF7 HTR3A IL2 MTHFR
4 immune system MP:0005387 10.07 ABCB1 CSF2 CSF3 EGF FGF7 HTR3A
5 endocrine/exocrine gland MP:0005379 10.06 ABCB1 CSF2 EGF HTR3A IL2 MTOR
6 integument MP:0010771 9.97 CSF2 CSF3 EGF FGF20 FGF7 HTR3A
7 nervous system MP:0003631 9.96 ABCB1 CSF2 FGF20 FGF7 HTR3A MTHFR
8 renal/urinary system MP:0005367 9.7 CSF2 CSF3 FGF7 HTR3A MTOR RSPO1
9 reproductive system MP:0005389 9.65 ABCB1 CSF2 DPYD EGF FGF7 HTR3A
10 skeleton MP:0005390 9.23 CSF2 DPYD FGF7 MTHFR MTOR RSPO1

Drugs & Therapeutics for Mucositis

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 582)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1400-61-9 11953884
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
5
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415 5280454
6
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
7
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
8
Melphalan Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 148-82-3 4053 460612
9
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
10
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124
11
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 171228-49-2 147912
12
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
13
Povidone Approved Phase 4,Phase 2,Not Applicable 9003-39-8
14
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
15
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3 7440-66-6
16
Metronidazole Approved Phase 4 443-48-1 4173
17
Hexetidine Approved, Investigational Phase 4 141-94-6
18
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
19
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
20
Budesonide Approved Phase 4,Phase 2 51333-22-3 63006 5281004
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
22
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
23
Capecitabine Approved, Investigational Phase 4,Phase 2 154361-50-9 60953
24
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 772 46507594
25
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2 100286-90-6, 97682-44-5 60838
26
Amifostine Approved, Investigational Phase 4,Phase 2 20537-88-6 2141
27
Promethazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-87-7 4927
28
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 51-45-6, 75614-87-8 774
29
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
30
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 137-58-6 3676
31
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3 1309-42-8
32
Aluminum hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3 21645-51-2
33
Simethicone Approved Phase 4 8050-81-5
34
Norethindrone Approved Phase 4 68-22-4 6230
35
Pantoprazole Approved Phase 4 102625-70-7 4679
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 77-92-9 311
37
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-81-7 5785 54670067
38
Camptothecin Experimental Phase 4,Phase 3,Phase 2 7689-03-4
39
Norethindrone enanthate Experimental Phase 4 3836-23-5
40 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Ionophores Phase 4,Phase 3,Phase 2
46 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 621)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
2 Oral Hygiene Regimen in Patients on HCT Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
3 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
4 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
5 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Unknown status NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
6 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
7 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4 Zinc;Placebo
8 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
9 Non Surgical Treatment of Periimplantitis Completed NCT02023853 Phase 4 metronidazole gel
10 Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
11 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
12 Tolerability, Efficacy and Mucosal Inflammation Associated With Orally Administered Colon Cleansing for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
13 Hexetidine and Chlorobutanol for Lesions Due to Prostheses Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
14 Mouth Care Regimes During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)
15 The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device Completed NCT02079792 Phase 4
16 Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients Completed NCT00204958 Phase 4 nutritional supplement;glutamine popsicle
17 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
18 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
20 The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma Completed NCT01305369 Phase 4 Prasugrel
21 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
22 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
23 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
24 Aloe Vera and Chlorhexidine Against Traumatic Oral Ulcers Completed NCT03633292 Phase 4 Antiseptic clorhexidine gel (Lacer, Barcelona, Spain);Master formula of aloe vera gel 80%
25 Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
26 Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer Recruiting NCT01707641 Phase 4
27 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
28 The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Recruiting NCT02905890 Phase 4 Norethisterone enantate
29 PPI and Microbiome in Healthy Volunteers Recruiting NCT03545243 Phase 4 Pantoprazole 40mg
30 Effect of Probiotic Lactobacillus Reuteri in the Treatment of Mucositis and Periimplantitis Active, not recruiting NCT03047291 Phase 4 Probiotic
31 Impact of Oral Hygiene Gels on Peri-implant Mucositis Active, not recruiting NCT03243591 Phase 4
32 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
33 Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
34 Low-energy Laser Therapy for Prevention of Oral Mucositis in Children Unknown status NCT01007617 Phase 2, Phase 3
35 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
36 Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation Unknown status NCT02313792 Phase 3 Palifermin
37 Lactobacillus Brevis CD2 Preventing Oral Mucositis Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
38 Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults Unknown status NCT02173756 Phase 3 morphine gel;placebo gel
39 Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation Unknown status NCT02282839 Phase 3
40 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
41 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
42 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
43 Omalizumab in Non-atopic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
44 COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma Unknown status NCT00603759 Phase 3 celecoxib;placebo
45 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
46 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
47 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
48 Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia Unknown status NCT01598402 Phase 2, Phase 3 amoxicillin/clavulanic acid suspension
49 Aprepitant Versus Olanzapine With High Dose Melphalan Unknown status NCT02939287 Phase 3 Aprepitant;Olanzapine
50 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Genetic Tests for Mucositis

Anatomical Context for Mucositis

MalaCards organs/tissues related to Mucositis:

41
Breast, Bone, Lung, Bone Marrow, T Cells, B Cells, Testes

Publications for Mucositis

Articles related to Mucositis:

(show top 50) (show all 1126)
# Title Authors Year
1
Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. ( 29926496 )
2018
2
Randomized clinical trial of a mucoadhesive formulation containing curcuminoids (Zingiberaceae) and Bidens pilosa Linn (Asteraceae) extract (FITOPROT) for prevention and treatment of oral mucositis - phase I study. ( 29906455 )
2018
3
Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials. ( 29893861 )
2018
4
Efficacy of Plantago major, chlorhexidine 0.12% and sodium bicarbonate 5% solution in the treatment of oral mucositis in cancer patients with solid tumour: A feasibility randomised triple-blind phase III clinical trial. ( 29353631 )
2018
5
Treatment of symptomatic oral mucositis with sodium hyaluronate and synthetic amino acid precursors of collagen in patients undergoing haematopoietic stem cell transplantation. ( 29921408 )
2018
6
Randomized, Double-Blind, Placebo-Controlled Trial of Shuanghua Baihe Tablets to Prevent Oral Mucositis in Patients With Nasopharyngeal Cancer Undergoing Chemoradiation Therapy. ( 29353657 )
2018
7
Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study. ( 29387994 )
2018
8
Dysplasia Should Not Be Ignored in Lichenoid Mucositis. ( 29328891 )
2018
9
Mycoplasma pneumoniae-associated mucositis with severe blistering stomatitis and pneumonia successfully treated with azithromycin and infusion therapy. ( 29952018 )
2018
10
Clinical Characteristics of Children and Adolescents Undergoing Hematopoietic Cell Transplantation Who Develop Oral Mucositis. ( 29947353 )
2018
11
Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. ( 29423682 )
2018
12
Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. ( 29926953 )
2018
13
Onset, progression and resolution of experimental peri-implant mucositis at different abutment surfaces: A randomized controlled two-centre study. ( 29331021 )
2018
14
The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )
2018
15
Peri-implant mucositis. ( 29926954 )
2018
16
Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. ( 29797142 )
2018
17
Effectiveness of Ankaferd Blood Stopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers and Evaluated with Plasma Citrulline Levels. ( 29391340 )
2018
18
A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. ( 29922939 )
2018
19
Radioprotective Effects of Dermatan Sulfate in a Preclinical Model of Oral Mucositis-Targeting Inflammation, Hypoxia and Junction Proteins without Stimulating Proliferation. ( 29882770 )
2018
20
Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( 29864944 )
2018
21
Evaluation of the Effect of Topical Application of Nigella sativa on Acute Radiation-Induced Nasal Mucositis. ( 29381633 )
2018
22
Probiotics and mucositis. ( 29916923 )
2018
23
Folate- producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis. ( 29969527 )
2018
24
Peri-implant mucositis. ( 29926488 )
2018
25
Factors Contributing to the Duration of Chemotherapy-Induced Severe Oral Mucositis in Oncopediatric Patients. ( 29865201 )
2018
26
Treatment of mucositis with combined 660- and 808-nm-wavelength low-level laser therapy reduced mucositis grade, pain, and use of analgesics: a parallel, single-blind, two-arm controlled study. ( 29948456 )
2018
27
Measuring the Quality of Life among Head-and/or-Neck Cancer Patients with Oral Mucositis Using the Functional Assessment of Cancer Therapy-General in Jordan. ( 29963595 )
2018
28
Clinical and microbiological evaluation of the effect of Lactobacillus reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial. ( 29352461 )
2018
29
Ellagitannins from Pomegranate Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Rats while Enhancing Its Chemotoxicity against HT-29 Colorectal Cancer Cells through Intrinsic Apoptosis Induction. ( 29920075 )
2018
30
Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis. ( 29445104 )
2018
31
Long-term control of laryngeal plasma cell mucositis with systemic immunosuppression. ( 29930164 )
2018
32
Fuchs syndrome: a case of fever, mucositis and conjunctivitis. ( 29378740 )
2018
33
Determination Relation of the Zinc Serum Level in Acute Leukemia Adult Patients with Mucositis and Neutropenic Prevalence before and after Treatment in Isfahan' Seyed-Al-Shohada Hospital, 2012-2013. ( 29531929 )
2018
34
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. ( 30290786 )
2018
35
Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. ( 29794809 )
2018
36
Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. ( 30350190 )
2018
37
Oral Complications in Children Undergoing Chemotherapy: The COMEDY (Clenching, Oral Mucositis, Eyes, DYsphagia) Pattern. ( 30475297 )
2018
38
The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi-center prospective feasibility study (EPOC study). ( 30225745 )
2018
39
Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. ( 29548299 )
2018
40
Factors Affecting the Incidence and Severity of Oral Mucositis Following Hematopoietic Stem Cell Transplantation. ( 30233777 )
2018
41
Impact of Oral and Gastrointestinal Mucositis on Body Weight Alterations during Hematopoietic Stem Cell Transplantation. ( 29278934 )
2018
42
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. ( 29545592 )
2018
43
Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment. ( 30479191 )
2018
44
Definitive radiotherapy for a head and neck Merkel cell carcinoma and comprehensive nodal volumes: a case for using a computer-designed variable-thickness compensator to reduce risk and severity of mucositis. ( 29031904 )
2018
45
Efficacy and safety of oral zinc sulfate in the prevention of chemotherapy-induced oral mucositis: Protocol for a meta-analysis of randomized controlled trials. ( 29794779 )
2018
46
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). ( 29805697 )
2018
47
A Judgement Bias Test to Assess Affective State and Potential Therapeutics in a Rat Model of Chemotherapy-Induced Mucositis. ( 29844396 )
2018
48
Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. ( 29845394 )
2018
49
Severity of Oral Mucositis in Children following Chemotherapy and Radiotherapy and Its Implications at a Single Oncology Centre in Durango State, Mexico. ( 29861749 )
2018
50
RRM1 gene expression evaluated in the liquid biopsy (blood cfRNA) as a non-invasive, predictive factor for radiotherapy-induced oral mucositis and potential prognostic biomarker in head and neck cancer patients. ( 29865035 )
2018

Variations for Mucositis

Expression for Mucositis

Search GEO for disease gene expression data for Mucositis.

Pathways for Mucositis

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CSF2 CSF3 EGF FGF20 FGF7 IL11
2
Show member pathways
13.47 EGF FGF20 FGF7 IL11 IL2 MTOR
3
Show member pathways
13.26 CSF2 CSF3 EGF FGF20 FGF7 IL11
4
Show member pathways
13.23 CSF2 CSF3 EGF FGF20 FGF7 IL11
5
Show member pathways
13.2 EGF FGF20 FGF7 IL2 TGFB3 VEGFA
6
Show member pathways
13.18 CSF2 CSF3 EGF FGF20 FGF7 IL11
7
Show member pathways
12.99 EGF FGF20 FGF7 IL2 MTOR TGFB3
8
Show member pathways
12.97 EGF FGF20 FGF7 IL2 MTOR TGFB3
9
Show member pathways
12.86 CSF3 EGF FGF20 FGF7 IL2 MTOR
10
Show member pathways
12.8 CSF2 EGF MTOR TGFB3 VEGFA
11
Show member pathways
12.71 EGF FGF20 FGF7 MTOR VEGFA
12 12.7 EGF FGF20 FGF7 TGFB3 VEGFA
13
Show member pathways
12.67 ABCB1 EGF FGF20 FGF7 MTOR TGFB3
14 12.63 EGF FGF20 FGF7 IL2 MTOR TGFB3
15
Show member pathways
12.62 EGF FGF20 FGF7 IL2 TGFB3
16
Show member pathways
12.41 EGF MTOR TGFB3 VEGFA
17
Show member pathways
12.33 EGF FGF20 FGF7 VEGFA
18
Show member pathways
12.31 EGF FGF20 FGF7 IL2 MTOR TGFB3
19
Show member pathways
12.19 FGF20 FGF7 IL2 TGFB3
20
Show member pathways
12.16 CSF2 CSF3 EGF IL11 IL2 MTOR
21 12 EGF FGF7 IL11 VEGFA
22 11.92 CSF2 CSF3 IL11 IL2
23 11.84 EGF MTOR VEGFA
24 11.83 CSF2 CSF3 IL11
25 11.8 EGF IL2 MTOR
26 11.75 CSF2 IL11 TGFB3 VEGFA
27 11.67 CSF2 IL2 TGFB3
28 11.66 EGF FGF20 FGF7 IL2 TGFB3
29 11.63 EGF IL2 MTOR
30
Show member pathways
11.6 CSF2 IL2 VEGFA
31
Show member pathways
11.51 EGF FGF20 FGF7 IL11 IL2 MTOR
32 11.5 CSF2 CSF3 EGF FGF7
33 11.39 EGF FGF7 VEGFA
34 11.24 EGF IL11 TGFB3 VEGFA
35 11.09 CSF2 CSF3 IL11 IL2 TGFB3
36 11.03 EGF FGF20 FGF7 VEGFA
37 10.92 CSF2 CSF3 IL11 IL2
38 10.85 ABCB1 MTOR
39 10.13 CSF2 CSF3 EGF FGF20 FGF7 IL11

GO Terms for Mucositis

Cellular components related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 CSF2 CSF3 EGF IL11 IL2 RSPO1
2 extracellular region GO:0005576 9.32 CSF2 CSF3 EGF FGF20 FGF7 IL11
3 platelet alpha granule lumen GO:0031093 9.13 EGF TGFB3 VEGFA

Biological processes related to Mucositis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 ABCB1 MTHFR TYMS XRCC1
2 positive regulation of protein phosphorylation GO:0001934 9.8 IL2 MTOR RSPO1 VEGFA
3 cytokine-mediated signaling pathway GO:0019221 9.8 CSF2 CSF3 IL11 IL2 VEGFA
4 platelet degranulation GO:0002576 9.79 EGF TGFB3 VEGFA
5 phosphatidylinositol phosphorylation GO:0046854 9.78 EGF FGF20 FGF7
6 peptidyl-tyrosine phosphorylation GO:0018108 9.78 CSF2 EGF FGF20 FGF7
7 response to hypoxia GO:0001666 9.76 MTHFR TGFB3 VEGFA XRCC1
8 regulation of signaling receptor activity GO:0010469 9.76 CSF2 CSF3 FGF20 FGF7 IL11 IL2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.74 CSF3 IL11 VEGFA
10 MAPK cascade GO:0000165 9.72 CSF2 EGF FGF20 FGF7 IL2
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CSF2 IL2 VEGFA
12 response to ethanol GO:0045471 9.67 CSF3 HTR3A IL2 TYMS
13 positive regulation of protein kinase B signaling GO:0051897 9.65 CSF3 EGF FGF20 FGF7 MTOR
14 positive regulation of cell division GO:0051781 9.61 FGF7 TGFB3 VEGFA
15 positive regulation of cell proliferation GO:0008284 9.61 CSF2 CSF3 EGF FGF20 FGF7 IL11
16 mammary gland alveolus development GO:0060749 9.6 EGF VEGFA
17 monocyte differentiation GO:0030224 9.59 CSF2 VEGFA
18 positive regulation of keratinocyte migration GO:0051549 9.58 FGF7 MTOR
19 tetrahydrofolate interconversion GO:0035999 9.56 MTHFR TYMS
20 tetrahydrofolate metabolic process GO:0046653 9.55 MTHFR TYMS
21 response to folic acid GO:0051593 9.52 MTHFR TYMS
22 voluntary musculoskeletal movement GO:0050882 9.51 MTOR XRCC1
23 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 CSF3 EGF FGF7 IL11 MTOR VEGFA

Molecular functions related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.56 CSF2 EGF FGF20 FGF7
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.55 CSF2 EGF FGF20 FGF7 IL2
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGF FGF20 FGF7
4 cytokine activity GO:0005125 9.43 CSF2 CSF3 IL11 IL2 TGFB3 VEGFA
5 growth factor activity GO:0008083 9.28 CSF2 CSF3 EGF FGF20 FGF7 IL11

Sources for Mucositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....